DCOY

Decoy Therapeutics Inc. (DCOY) Economic Moat Analysis (2026)

Invetso Score: 1.1/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 1.2 (Weak)

No filing evidence provided of proprietary brands, patents, or regulatory licenses that would let DCOY charge premium prices versus peers, so pricing power appears structurally limited.

The available metrics show negative ROIC and no margin history, which is consistent with weak monetization of any intangible asset base relative to peers.

Without disclosed customer lock-in or protected IP, any intangible advantage appears replicable and unlikely to sustain retention or margins over 5–10 years.

Compared with peers that have identifiable IP, brand equity, or regulated franchises, DCOY shows no visible evidence of a durable intangible moat.

Switching Costs

Score:

No evidence was provided of contracts, workflow integration, or embedded systems that would make customers costly to replace, so switching costs appear minimal.

Negative ROIC and absent operating margin history suggest customers are not locked in strongly enough to support durable pricing power versus peers.

There is no disclosed ecosystem dependency or data migration burden that would materially raise churn costs over time.

Relative to peers with subscription, platform, or regulated-service lock-in, DCOY appears far easier to substitute.

Network Effects

Score:

No evidence indicates that DCOY benefits from user-to-user, buyer-seller, or data network effects that would compound advantage versus peers.

The provided metrics do not show scale-driven margin expansion, which is what would typically accompany a meaningful network effect.

Absent a growing ecosystem or multi-sided platform, customer value does not appear to increase as adoption rises.

Compared with peers that gain stronger utility from each additional participant, DCOY shows no visible network-based moat.

Cost Advantage

Score:

Negative ROIC and no margin data argue against a persistent unit-cost advantage that would let DCOY underprice peers while preserving returns.

The zero asset-turnover figure provided does not support evidence of superior operating efficiency versus competitors.

No filing evidence was provided for proprietary supply chain, scale purchasing, or process advantages that would lower costs structurally.

Relative to peers with demonstrated scale economies or lower cost-to-serve, DCOY does not show a durable cost edge.

Efficient Scale

Score:

No evidence suggests DCOY operates in a niche market where one or two firms can profitably serve demand and deter entry, so efficient-scale protection appears absent.

Negative ROIC implies the business is not extracting scarcity rents from a constrained market structure versus peers.

There is no disclosed regulatory barrier or capacity constraint that would limit competition and preserve returns over time.

Compared with peers in concentrated or regulated markets, DCOY appears exposed to normal competitive entry and substitution.

Overall Score

Score:

DCOY shows no visible structural moat in the provided evidence, and the negative ROIC plus lack of margin history point to weak pricing power, retention, and cost discipline versus peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Decoy Therapeutics Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →